Tag Archives: paroxysmal nocturnal hemoglobinuria

December, 2018

August, 2018

January, 2017

  • 9 January

    FDA Grants Orphan Drug Designation To Alexion’s ALXN1210 For PNH

    NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement, which is being evaluated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH …